Literature DB >> 28704198

Alzheimer's disease: as it was in the beginning.

Stanislav Kozlov1, Alexei Afonin1, Igor Evsyukov1, Andrei Bondarenko1.   

Abstract

Since Alzheimer's disease was first described in 1907, many attempts have been made to reveal its main cause. Nowadays, two forms of the disease are known, and while the hereditary form of the disease is clearly caused by mutations in one of several genes, the etiology of the sporadic form remains a mystery. Both forms share similar sets of neuropathological and molecular manifestations, including extracellular deposition of amyloid-beta, intracellular accumulation of hyperphosphorylated tau protein, disturbances in both the structure and functions of mitochondria, oxidative stress, metal ion metabolism disorders, impairment of N-methyl-D-aspartate receptor-related signaling pathways, abnormalities of lipid metabolism, and aberrant cell cycle reentry in some neurons. Such a diversity of symptoms led to proposition of various hypotheses for explaining the development of Alzheimer's disease, the amyloid hypothesis, which postulates the key role of amyloid-beta in Alzheimer's disease development, being the most prominent. However, this hypothesis does not fully explain all of the molecular abnormalities and is therefore heavily criticized. In this review, we propose a hypothetical model of Alzheimer's disease progression, assuming a key role of age-related mitochondrial dysfunction, as was postulated in the mitochondrial cascade hypothesis. Our model explains the connections between all the symptoms of Alzheimer's disease, with particular attention to autophagy, metal metabolism disorders, and aberrant cell cycle re-entry in neurons. Progression of the Alzheimer's disease appears to be a complex process involving aging and too many protective mechanisms affecting one another, thereby leading to even greater deleterious effects.

Entities:  

Keywords:  amyloid beta; autophagy; iron; mitochondrial dysfunction; neurofibrillary tangles; neuronal cell cycle re-entry; β-amyloid

Mesh:

Substances:

Year:  2017        PMID: 28704198     DOI: 10.1515/revneuro-2017-0006

Source DB:  PubMed          Journal:  Rev Neurosci        ISSN: 0334-1763            Impact factor:   4.353


  25 in total

Review 1.  Alzheimer's Disease: The Link Between Amyloid-β and Neurovascular Dysfunction.

Authors:  Ernesto Solis; Kevin N Hascup; Erin R Hascup
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

2.  Targeting Iron Dyshomeostasis for Treatment of Neurodegenerative Disorders.

Authors:  Niels Bergsland; Eleonora Tavazzi; Ferdinand Schweser; Dejan Jakimovski; Jesper Hagemeier; Michael G Dwyer; Robert Zivadinov
Journal:  CNS Drugs       Date:  2019-11       Impact factor: 5.749

3.  Identification of new BACE1 inhibitors for treating Alzheimer's disease.

Authors:  Pragya Kushwaha; Vineeta Singh; Pallavi Somvanshi; Tulika Bhardwaj; George E Barreto; Ghulam Md Ashraf; Bhartendu Nath Mishra; Rajendra Singh Chundawat; Shafiul Haque
Journal:  J Mol Model       Date:  2021-01-30       Impact factor: 1.810

Review 4.  Sphingolipids and lipid rafts: Novel concepts and methods of analysis.

Authors:  Erhard Bieberich
Journal:  Chem Phys Lipids       Date:  2018-09-05       Impact factor: 3.329

Review 5.  Mitochondrial Iron in Human Health and Disease.

Authors:  Diane M Ward; Suzanne M Cloonan
Journal:  Annu Rev Physiol       Date:  2018-11-28       Impact factor: 19.318

6.  Late-onset Alzheimer's disease is associated with inherent changes in bioenergetics profiles.

Authors:  Kai-C Sonntag; Woo-In Ryu; Kristopher M Amirault; Ryan A Healy; Arthur J Siegel; Donna L McPhie; Brent Forester; Bruce M Cohen
Journal:  Sci Rep       Date:  2017-10-25       Impact factor: 4.379

7.  Dietary Protein Source Influences Brain Inflammation and Memory in a Male Senescence-Accelerated Mouse Model of Dementia.

Authors:  Sabrina Petralla; Cristina Parenti; Valentina Ravaioli; Irene Fancello; Francesca Massenzio; Marco Virgili; Barbara Monti; Emiliano Pena-Altamira
Journal:  Mol Neurobiol       Date:  2020-11-09       Impact factor: 5.590

8.  Clinical pharmacokinetic study of latrepirdine via in silico sublingual administration.

Authors:  Joana Santos; Luísa Lobato; Nuno Vale
Journal:  In Silico Pharmacol       Date:  2021-04-05

Review 9.  Cognitive Impairment in Older Adults and Therapeutic Strategies.

Authors:  Thomas J Montine; Syed A Bukhari; Lon R White
Journal:  Pharmacol Rev       Date:  2021-01       Impact factor: 25.468

Review 10.  Mitochondrial Dysfunction as a Driver of Cognitive Impairment in Alzheimer's Disease.

Authors:  Chanchal Sharma; Sehwan Kim; Youngpyo Nam; Un Ju Jung; Sang Ryong Kim
Journal:  Int J Mol Sci       Date:  2021-05-03       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.